



TO: Our Valued Clients and Brokers
FROM: Health Plans, Inc.
DATE: May 18, 2023
RE: Compliance *eBlast*: RxDC Reporting Submission Notice

Health Plans, Inc. (HPI) is issuing this Compliance *eBlast* to notify you of HPI's successful filing for the 2022 Prescription Drug Data Collection (RxDC) Reporting cycle pursuant to the Consolidated Appropriations Act of 2021.

HPI communicated our approach for the 2022 RxDC Report as detailed in our 2/24/2023 Compliance *eBlast* found [here](#) – HPI submitted D2 Medical Data for any months during 2022 that clients' plans were active with HPI along with a P2 Plan List and a Narrative Response. We also submitted the D1 Premium and Life Years data for clients who opted in to have HPI perform this service.

For reference:
Submission ID: 13354
Submission Name: initial2022
Submission Date: 5/16/2023

For best service, please contact your HPI Account Service Team directly if you have any questions.

Regards,

Andrew H. A. Meggison
Director, Regulatory Affairs
HealthPlansInc.com
1500 West Park Drive, Suite 330
Westborough, MA 01581

The information in this Compliance *eBlast* is intended to provide a summary of our understanding of recent regulatory developments which may affect our clients' plans. It should not be construed as specific legal advice or legal opinion.